KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for Aquestive Therapeutics (AQST) over the last 6 years, with Dec 2024 value amounting to $20.0 million.

  • Aquestive Therapeutics' Non-Current Deffered Revenue fell 2.98% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 million, marking a year-over-year decrease of 2.98%. This contributed to the annual value of $20.0 million for FY2024, which is 38.15% down from last year.
  • As of FY2024, Aquestive Therapeutics' Non-Current Deffered Revenue stood at $20.0 million, which was down 38.15% from $32.3 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Non-Current Deffered Revenue high stood at $32.3 million for FY2023, and its period low was $3.6 million during FY2020.
  • Over the past 3 years, Aquestive Therapeutics' median Non-Current Deffered Revenue value was $31.4 million (recorded in 2022), while the average stood at $27.9 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Non-Current Deffered Revenue spiked by 341.13% in 2022, and later slumped by 38.15% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Non-Current Deffered Revenue stood at $3.6 million in 2020, then surged by 96.04% to $7.1 million in 2021, then spiked by 341.13% to $31.4 million in 2022, then rose by 2.95% to $32.3 million in 2023, then slumped by 38.15% to $20.0 million in 2024.